⌕
MapLight Therapeutics · MPLT · Nasdaq
Tenet 74 · Solid
Compare
$6.90−4.83%At closeTenet 74 · Solid
$6.90−0.35 (−4.83%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

MapLight Therapeutics (MPLT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The four lines that matter · FY24–FY25
Revenue ($M)—
0.0
FY24→FY25CAGR —
Net income ($M)▼107.7%
−161.2
FY24→FY25CAGR —
Free cash flow ($M)▼74.2%
−138.6
FY24→FY25CAGR —
Diluted EPS▲82.4%
−18.56
FY24→FY25CAGR —
What the income statement says · FY24–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−138.3R&D−30.7SG&A−169.1Op income7.9Tax & other−161.2Net income

Margin trend · direction beats level
00000%FY24FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY24–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.1635, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
Line itemTTM †FY25FY24YoYCAGR 24→25
Revenue & profitability
Revenue
—0.00.0——
Cost of revenue
—0.00.0——
Gross profit
—0.00.0——
Research & development
215.9138.368.5▲101.9%—
Selling, general & admin
50.830.714.4▲113.1%—
Total operating expenses
266.8169.182.9▲103.8%—
Operating incomefeeds ROC rank
−266.8−169.1−82.9▼103.8%—
Other income, net
14.77.95.4——
Pretax income
−252.0−161.2−77.6▼107.7%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−252.0−161.2−77.6▼107.7%—
Per share
Diluted EPSbuyback-sensitive
—−18.56−105.38▲82.4%—
Diluted shares (mn)
—8.680.74▲1079.2%—
Margins
† TTM = trailing four quarters through 2026-09-30.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.